Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Jazz Pharmaceuticals PLC    JAZZ   IE00B4Q5ZN47

JAZZ PHARMACEUTICALS PLC

(JAZZ)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Jazz Pharmaceuticals : Announces Webcast for Sunosi Investor Update

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/25/2019 | 04:06pm EDT

DUBLIN, June 25, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast on Tuesday, July 2, 2019 at 4:30 p.m. EDT/9:30 p.m. IST to provide investors with an update on Sunosi™ (solriamfetol), which was approved by the U.S. Food and Drug Administration on March 20, 2019 to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA).  Sunosi is the first dual-acting dopamine and norepinephrine reuptake inhibitor approved to treat excessive daytime sleepiness in adults living with narcolepsy or OSA.  Beginning early July, Sunosi will be commercially available in the U.S. following the recent scheduling decision by the U.S. Drug Enforcement Agency.

The investor webcast will include an overview of narcolepsy and OSA from invited physician experts as well as a Sunosi overview from the company's senior management.

A live audio webcast of the presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com.  Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

An archive of the webcast will be available for at least one week following the presentation on the Investors section of the company's website at www.jazzpharmaceuticals.com.

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ), a global biopharmaceutical company, is dedicated to developing life-changing medicines for people with limited or no options.  As a leader in sleep medicine and with a growing hematology/oncology portfolio, Jazz has a diverse portfolio of products and product candidates in development, and is focused on transforming biopharmaceutical discoveries into novel medicines.  Jazz Pharmaceuticals markets SunosiTM (solriamfetol), Xyrem® (sodium oxybate) oral solution, Defitelio® (defibrotide sodium), Erwinaze® (asparaginase Erwinia chrysanthemi) and Vyxeos® (daunorubicin and cytarabine) liposome for injection in the U.S. and markets Defitelio® (defibrotide), Erwinase® and Vyxeos® 44 mg/100 mg powder for concentrate for solution for infusion in countries outside the U.S.  For country-specific product information, please visit www.jazzpharmaceuticals.com/medicines.  For more information, please visit www.jazzpharmaceuticals.com and follow us on Twitter at @JazzPharma.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements, including, but not limited to, statements related to the expected timing of commercial availability of Sunosi in the U.S. and other statements that are not historical facts.  These forward-looking statements are based on the company's current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties.  Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with: delays or problems in the supply or manufacture of Sunosi; complying with applicable U.S. regulatory requirements; and other risks and uncertainties affecting the company, including those described from time to time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals plc's Securities and Exchange Commission filings and reports (Commission File No. 001-33500), including the company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2019 and future filings and reports by the company.  Other risks and uncertainties of which the company is not currently aware may also affect the company's forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated.  The forward-looking statements herein are made only as of the date hereof or as of the dates indicated in the forward-looking statements, even if they are subsequently made available by the company on its website or otherwise.  The company undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.

Jazz Pharmaceuticals Logo (PRNewsFoto/Jazz Pharmaceuticals plc) (PRNewsFoto/Jazz Pharmaceuticals plc)

 

Cision
View original content to download multimedia:http://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-webcast-for-sunosi-investor-update-300874663.html

SOURCE Jazz Pharmaceuticals plc


© PRNewswire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JAZZ PHARMACEUTICALS PLC
07/10JAZZ PHARMACEUTICALS : Acquires Pre-clinical Pan-RAF Inhibitor Program from Redx..
PR
06/25JAZZ PHARMACEUTICALS : Announces Webcast for Sunosi Investor Update
PR
06/17JAZZ PHARMACEUTICALS : Receives Schedule IV Designation from DEA for Sunosi&trad..
PU
06/03JAZZ PHARMACEUTICALS : Appoints Dr. Robert Iannone as Executive Vice President, ..
PR
05/09JAZZ PHARMACEUTICALS : Data to Showcase Ongoing Sleep Medicine Research at SLEEP..
PR
05/06JAZZ PHARMACEUTICALS : Announces Participation in Two Upcoming Investor Conferen..
PR
04/23JAZZ PHARMACEUTICALS : to Report 2019 First Quarter Financial Results on May 7, ..
PR
04/04Three Drug Companies to Pay $122.6 Million to Resolve Kickback Allegations--2..
DJ
04/04Three Drug Companies to Pay $122.6 Million to Resolve Kickback Allegations--U..
DJ
04/04Three Drug Companies to Pay $122.6 Million to Resolve Kickback Allegations
DJ
More news